Psycheceutical, Inc. has announced it has entered into a strategic agreement with Vici Health Sciences, known for providing pharmaceutical clients with tools to innovate and grow through new product development. Through this relationship, Psycheceutical will be able to test and develop its patented technologies and continue its focus on exploring the formulation of unique, branded compounds.
Esteemed neurosurgeon to participate in strategy, direction for development of novel psychedelic therapy innovations.
Psycheceutical, Inc., today announced the company has been fully acquired by Blue Water Ventures International, Inc. (OTCPK: BWVI).
Psycheceutical, Inc., today announced the addition of Zachary Clayton, PhD, to its scientific advisory board.
Psycheceutical, Inc., today announced the growth of its esteemed board with two new appointments, Dr. Ronald Aung-Din and Dr. John Kutzko.
Psycheceutical, Inc., today announced its exclusive license within the entire psychedelic industry of two major patents that will significantly advance the medical application of psychedelic compounds.